Mylan Talks Up Prospects For Becoming Leader In Generic Injectables

02 Aug 2013

• By Lisa LaMotta

The generic drug maker has set ambitious price targets for its stock over the next five years based on recently acquired assets and some risky generic drug launches. Analysts are concerned the company is putting too much faith in high-risk projects.

Mylan NV is positioned to become a major player in the specialty injectables business as it incorporates its acquisition of Agila Specialties Pvt. Ltd., which is set to close later this year. Meanwhile, the company is preparing for some high-profile, high-risk generic launches, said the company at an analyst meeting held in New York on Aug. 1.

In February, Mylan ended months of speculation and announced that it was buying Strides Shasun Ltd.’s highly profitable injectable...